The FDA approved a novel, faster-acting insulin lispro injection to improve glycemic response in adults with type 1 and type 2 diabetes, according to a press release from Eli Lilly. Insulin lispro ...

First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter multiple-dose vial, making it readily accessible for personal and ...

The FDA approved an expanded label for rapid-acting insulin lispro-aabc injection to include administration via continuous subcutaneous infusion with an insulin pump, according to an industry ...

Novo Nordisk announced that the FDA has approved its insulin aspart injection Fiasp, which can rapidly improve glycemic control at mealtimes for patients with type 1 and type 2 diabetes.

FDA approves Lyumjev™ (insulin lispro-aabc injection), Lilly's new rapid-acting insulin. PR Newswire. INDIANAPOLIS, June 15, 2020. ... Humalog is a fast-acting insulin.

The FDA agreed that Viatris Inc.'s Semglee was interchangeable with widely used Lantus, a fast-acting insulin.

Exubera today became the first inhaled insulin to get FDA approval. Exubera delivers short-acting insulin via an inhaler. It offers adults with type 1 or type 2 diabetes an alternative to the ...

“The FDA has now approved three biosimilar insulin products to treat diabetes,” noted Peter Stein, M.D., director of the Office of New Drugs in the FDA’s Center for Drug Evaluation and Research.

SILVER SPRING, Md., Feb. 14, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement ...

According to the FDA, more than 38 million people in the United States have been diagnosed with diabetes, and approximately 8.4 million Americans rely on insulin therapy, either rapid-acting or ...

FDA approves first rapid-acting insulin biosimilar product for treatment of diabetes. News release. US Food and Drug Administration. February 14, 2025.

FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes By Stephanie Brown HealthDay Reporter WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- The U.S. Food and Drug ...